Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Elaine Lam

Concepts (314)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Carcinoma, Renal Cell
37
2026
229
7.090
 Why?
Kidney Neoplasms
40
2026
405
6.660
 Why?
Prostatic Neoplasms
13
2023
976
2.860
 Why?
Neoplasms, Germ Cell and Embryonal
3
2023
76
1.450
 Why?
Antineoplastic Agents
15
2024
2172
1.300
 Why?
Prostate-Specific Antigen
4
2023
157
1.160
 Why?
Antibodies, Monoclonal, Humanized
12
2025
932
1.130
 Why?
Antineoplastic Combined Chemotherapy Protocols
15
2025
1833
1.030
 Why?
Protein Kinase Inhibitors
12
2026
976
1.020
 Why?
Neoplasms
10
2023
2798
0.910
 Why?
Testicular Neoplasms
3
2023
112
0.910
 Why?
Neoplasms, Unknown Primary
1
2025
19
0.900
 Why?
Antineoplastic Agents, Immunological
2
2025
194
0.850
 Why?
Carcinoma, Transitional Cell
4
2025
68
0.800
 Why?
Seminoma
2
2021
20
0.790
 Why?
Carcinoma, Medullary
2
2013
16
0.720
 Why?
Aged
37
2026
25298
0.700
 Why?
Retroperitoneal Neoplasms
1
2021
27
0.680
 Why?
Urinary Bladder Neoplasms
4
2025
251
0.670
 Why?
Male
60
2026
71079
0.660
 Why?
Pyridines
6
2026
596
0.650
 Why?
Pneumocystis carinii
1
2020
12
0.630
 Why?
Teratoma
1
2021
120
0.630
 Why?
Spinal Cord Compression
1
2020
21
0.630
 Why?
Carcinoma, Squamous Cell
1
2025
639
0.630
 Why?
Trimethoprim, Sulfamethoxazole Drug Combination
1
2020
42
0.630
 Why?
Pneumonia, Pneumocystis
1
2020
35
0.620
 Why?
Humans
87
2026
142694
0.580
 Why?
Euterpe
1
2018
4
0.580
 Why?
Middle Aged
39
2026
35226
0.550
 Why?
TWEAK Receptor
1
2017
6
0.540
 Why?
Prednisone
3
2020
222
0.540
 Why?
Pyrazoles
3
2022
496
0.530
 Why?
Anilides
5
2023
80
0.520
 Why?
Sulfonamides
3
2015
569
0.510
 Why?
Abiraterone Acetate
1
2017
15
0.510
 Why?
Biomarkers, Tumor
6
2025
1285
0.510
 Why?
Plant Extracts
1
2018
194
0.500
 Why?
Adrenal Cortex Hormones
1
2020
498
0.500
 Why?
Aged, 80 and over
17
2025
8009
0.490
 Why?
Antineoplastic Agents, Hormonal
2
2015
171
0.470
 Why?
Neoplasm Recurrence, Local
3
2023
1096
0.460
 Why?
Neoplasm Metastasis
9
2020
678
0.460
 Why?
Carcinoma, Papillary
1
2015
78
0.450
 Why?
Brain Neoplasms
2
2021
1301
0.440
 Why?
Paclitaxel
3
2022
237
0.430
 Why?
Everolimus
2
2025
111
0.420
 Why?
Patient Reported Outcome Measures
4
2025
461
0.420
 Why?
Prostatic Neoplasms, Castration-Resistant
3
2022
50
0.420
 Why?
Interleukin-2
2
2014
445
0.410
 Why?
Neoplasms, Complex and Mixed
1
2013
7
0.410
 Why?
Antibodies, Monoclonal
2
2017
1469
0.390
 Why?
Urologic Neoplasms
2
2025
31
0.380
 Why?
Treatment Outcome
17
2025
11341
0.370
 Why?
Nephrectomy
4
2024
156
0.370
 Why?
Retrospective Studies
18
2024
16647
0.360
 Why?
Epothilones
1
2011
1
0.360
 Why?
Carcinoma, Non-Small-Cell Lung
3
2025
1144
0.350
 Why?
Angiomyolipoma
1
2011
21
0.350
 Why?
Androgen Antagonists
3
2020
92
0.350
 Why?
Deoxycytidine
2
2010
201
0.330
 Why?
Multicenter Studies as Topic
1
2012
388
0.330
 Why?
Adult
27
2025
39755
0.320
 Why?
Benzenesulfonates
1
2010
22
0.320
 Why?
Lung Neoplasms
4
2025
2589
0.320
 Why?
Suramin
1
2010
7
0.320
 Why?
Maximum Tolerated Dose
6
2022
206
0.300
 Why?
Radiosurgery
3
2019
390
0.290
 Why?
Female
35
2026
76894
0.290
 Why?
Immunotherapy
5
2024
661
0.280
 Why?
Indenes
2
2025
6
0.280
 Why?
Fluorouracil
1
2008
209
0.270
 Why?
Disease Progression
3
2021
2851
0.260
 Why?
Bone Neoplasms
2
2023
249
0.260
 Why?
Quinazolines
1
2008
261
0.260
 Why?
Chemotherapy, Adjuvant
3
2013
388
0.250
 Why?
Neoplasm Staging
7
2017
1412
0.250
 Why?
Practice Guidelines as Topic
4
2024
1521
0.250
 Why?
Platinum
2
2024
50
0.240
 Why?
Drug Administration Schedule
3
2021
766
0.240
 Why?
Thyroid Neoplasms
1
2010
337
0.240
 Why?
Proto-Oncogene Proteins c-kit
1
2026
72
0.230
 Why?
Sulfones
2
2017
127
0.230
 Why?
B7-H1 Antigen
2
2025
240
0.230
 Why?
Microsatellite Instability
1
2025
50
0.220
 Why?
Prognosis
5
2023
4159
0.220
 Why?
Phenylurea Compounds
4
2016
100
0.220
 Why?
Benzoxazoles
2
2022
19
0.210
 Why?
Ipilimumab
2
2021
39
0.200
 Why?
Taste
1
2026
234
0.200
 Why?
Melanoma
2
2025
797
0.200
 Why?
Taxoids
2
2017
107
0.200
 Why?
Taste Buds
1
2026
209
0.200
 Why?
Bevacizumab
2
2020
141
0.190
 Why?
Multiple Sclerosis
2
2019
481
0.190
 Why?
Kaplan-Meier Estimate
5
2024
917
0.190
 Why?
Mastectomy
1
2023
162
0.180
 Why?
Quantitative Trait Loci
1
2024
366
0.180
 Why?
Pyrimidines
3
2022
523
0.180
 Why?
Remission, Spontaneous
1
2021
40
0.170
 Why?
Administration, Oral
4
2024
834
0.170
 Why?
Biliary Tract Neoplasms
1
2021
30
0.170
 Why?
Neoplasm, Residual
1
2021
134
0.160
 Why?
Celecoxib
2
2012
41
0.160
 Why?
Carboplatin
1
2021
144
0.160
 Why?
Bariatric Surgery
1
2024
232
0.160
 Why?
Phosphatidylinositol 3-Kinases
1
2022
378
0.160
 Why?
Syndrome
1
2021
371
0.160
 Why?
Proto-Oncogene Proteins c-akt
1
2022
439
0.160
 Why?
Quality of Life
2
2025
3068
0.160
 Why?
Combined Modality Therapy
4
2019
1242
0.160
 Why?
Genomics
1
2025
819
0.150
 Why?
Azepines
1
2020
106
0.150
 Why?
Cancer Care Facilities
1
2020
45
0.150
 Why?
Antiemetics
1
2020
49
0.150
 Why?
Homologous Recombination
1
2019
30
0.150
 Why?
Thrombosis
1
2023
390
0.150
 Why?
Fatal Outcome
1
2020
305
0.150
 Why?
Morpholines
1
2020
125
0.150
 Why?
TOR Serine-Threonine Kinases
1
2022
446
0.150
 Why?
MAP Kinase Kinase Kinases
1
2019
70
0.150
 Why?
Pharyngitis
1
2019
25
0.150
 Why?
Streptococcus
1
2019
29
0.140
 Why?
Disease-Free Survival
4
2016
727
0.140
 Why?
Fruit and Vegetable Juices
1
2018
17
0.140
 Why?
Anti-Bacterial Agents
2
2020
1892
0.140
 Why?
Drug Hypersensitivity
1
2020
90
0.140
 Why?
Diagnosis, Computer-Assisted
1
2019
92
0.140
 Why?
Feedback
1
2019
181
0.140
 Why?
Mutation
2
2025
4024
0.140
 Why?
Indans
1
2017
13
0.140
 Why?
Cost-Benefit Analysis
1
2021
614
0.140
 Why?
Neoplastic Cells, Circulating
2
2016
80
0.140
 Why?
Interferon beta-1b
1
2017
2
0.130
 Why?
Pancreatic Neoplasms
1
2026
924
0.130
 Why?
Niacinamide
3
2016
82
0.130
 Why?
Genome-Wide Association Study
1
2024
1442
0.130
 Why?
Proton Therapy
1
2017
15
0.130
 Why?
Liver Neoplasms
1
2023
763
0.130
 Why?
Erythrocytes, Abnormal
1
2016
14
0.130
 Why?
Streptococcal Infections
1
2019
160
0.120
 Why?
Dose-Response Relationship, Drug
3
2022
2008
0.120
 Why?
Polymorphism, Single Nucleotide
1
2024
2150
0.120
 Why?
Multiple Sclerosis, Relapsing-Remitting
1
2017
81
0.120
 Why?
Hematologic Diseases
1
2016
67
0.120
 Why?
DNA Damage
1
2019
429
0.120
 Why?
Neoadjuvant Therapy
2
2023
441
0.120
 Why?
Cell Line, Tumor
3
2020
3558
0.120
 Why?
Oncolytic Virotherapy
1
2015
14
0.120
 Why?
Problem Solving
1
2017
151
0.120
 Why?
Indazoles
2
2015
78
0.120
 Why?
Mammalian orthoreovirus 3
1
2015
37
0.120
 Why?
Autoimmune Diseases
1
2020
462
0.120
 Why?
Angiopoietin-1
1
2015
11
0.110
 Why?
Angiopoietin-2
1
2015
14
0.110
 Why?
Pyrroles
1
2016
210
0.110
 Why?
Genetic Predisposition to Disease
1
2024
2395
0.110
 Why?
Fatigue
2
2022
352
0.110
 Why?
Receptor, IGF Type 1
1
2015
63
0.110
 Why?
Imidazoles
2
2015
249
0.110
 Why?
Kidney Glomerulus
1
2015
128
0.110
 Why?
Nanoparticles
1
2021
509
0.110
 Why?
Radiation Tolerance
1
2015
103
0.110
 Why?
Proto-Oncogene Proteins p21(ras)
1
2015
260
0.110
 Why?
Soft Tissue Neoplasms
1
2015
123
0.110
 Why?
Severity of Illness Index
2
2019
2905
0.100
 Why?
Magnetic Resonance Imaging
2
2021
3808
0.100
 Why?
Prefrontal Cortex
1
2017
324
0.100
 Why?
Receptors, Vascular Endothelial Growth Factor
2
2013
107
0.100
 Why?
Prostatectomy
1
2013
89
0.100
 Why?
Patient Satisfaction
1
2017
692
0.100
 Why?
Indoles
1
2016
474
0.090
 Why?
Glycine
1
2014
181
0.090
 Why?
Cohort Studies
5
2021
5820
0.090
 Why?
Recombinant Fusion Proteins
1
2015
673
0.090
 Why?
Quinolines
1
2013
174
0.090
 Why?
Glomerular Filtration Rate
1
2015
750
0.090
 Why?
Tubulin Modulators
1
2011
11
0.090
 Why?
Metabolic Clearance Rate
1
2011
116
0.090
 Why?
Emotions
1
2017
571
0.090
 Why?
Algorithms
1
2019
1816
0.080
 Why?
Arthralgia
1
2011
58
0.080
 Why?
Area Under Curve
1
2011
331
0.080
 Why?
Clinical Trials as Topic
1
2015
1038
0.080
 Why?
Breast Neoplasms
1
2023
2334
0.080
 Why?
Peripheral Nervous System Diseases
1
2011
130
0.080
 Why?
Diarrhea
1
2011
188
0.080
 Why?
Mechanistic Target of Rapamycin Complex 1
2
2022
138
0.080
 Why?
Molecular Structure
1
2011
498
0.080
 Why?
Proto-Oncogene Proteins c-ret
1
2010
40
0.080
 Why?
Biopsy
1
2013
1064
0.080
 Why?
Survival Rate
3
2020
2003
0.080
 Why?
Decision Making
1
2017
952
0.080
 Why?
Nomograms
1
2010
58
0.080
 Why?
Tomography, X-Ray Computed
3
2022
2775
0.070
 Why?
Immunohistochemistry
1
2013
1722
0.070
 Why?
Radiotherapy, Adjuvant
1
2010
215
0.070
 Why?
Drug Synergism
1
2010
358
0.070
 Why?
Capecitabine
1
2008
42
0.070
 Why?
Infusions, Intravenous
1
2010
420
0.070
 Why?
Adenine
2
2022
331
0.070
 Why?
Positron-Emission Tomography
1
2010
314
0.070
 Why?
Proteinuria
1
2008
102
0.070
 Why?
Hypertension, Pregnancy-Induced
1
2008
68
0.070
 Why?
Dysgeusia
1
2026
5
0.060
 Why?
Young Adult
4
2024
13817
0.060
 Why?
Follow-Up Studies
3
2020
5276
0.060
 Why?
Creatinine
1
2008
491
0.060
 Why?
Risk
1
2008
897
0.060
 Why?
Optical Illusions
1
2005
2
0.060
 Why?
Urothelium
1
2025
33
0.060
 Why?
Risk Factors
2
2020
10569
0.050
 Why?
Von Hippel-Lindau Tumor Suppressor Protein
1
2024
15
0.050
 Why?
Cell Lineage
1
2026
374
0.050
 Why?
Cytoreduction Surgical Procedures
1
2024
68
0.050
 Why?
Prospective Studies
3
2021
7845
0.050
 Why?
Mastectomy, Segmental
1
2023
101
0.050
 Why?
Adjuvants, Immunologic
1
2024
238
0.050
 Why?
RNA Interference
1
2024
474
0.050
 Why?
Cardiovascular Diseases
1
2014
2095
0.050
 Why?
Disease Management
2
2017
636
0.050
 Why?
RNA, Small Interfering
1
2024
638
0.040
 Why?
Cisplatin
1
2023
331
0.040
 Why?
Nephritis, Interstitial
1
2020
11
0.040
 Why?
International Agencies
1
2020
31
0.040
 Why?
Drug Evaluation
1
2020
79
0.040
 Why?
Aurora Kinase A
1
2020
62
0.040
 Why?
Mechanistic Target of Rapamycin Complex 2
1
2020
62
0.040
 Why?
Lymphocytes
1
2022
390
0.040
 Why?
Nausea
1
2020
111
0.040
 Why?
Analysis of Variance
2
2017
1301
0.040
 Why?
Hong Kong
1
2019
8
0.040
 Why?
Vomiting
1
2020
130
0.040
 Why?
Time Factors
1
2010
7010
0.040
 Why?
Lymphatic Metastasis
1
2020
326
0.040
 Why?
Sex Factors
1
2025
2066
0.040
 Why?
Medical Oncology
1
2022
319
0.040
 Why?
Hospitals
1
2023
691
0.040
 Why?
Mice, Knockout
1
2026
3110
0.040
 Why?
DNA-Binding Proteins
1
2026
1483
0.040
 Why?
Central Nervous System
1
2020
271
0.030
 Why?
Cell Differentiation
1
2026
2029
0.030
 Why?
Transcription Factors
1
2026
1727
0.030
 Why?
Genetic Testing
1
2020
471
0.030
 Why?
Retreatment
1
2017
74
0.030
 Why?
Databases, Factual
1
2023
1452
0.030
 Why?
United States
2
2017
15499
0.030
 Why?
Drug Therapy, Combination
1
2020
1031
0.030
 Why?
National Cancer Institute (U.S.)
1
2017
48
0.030
 Why?
Receptor Protein-Tyrosine Kinases
1
2019
227
0.030
 Why?
Erythrocyte Indices
1
2016
31
0.030
 Why?
Xenograft Model Antitumor Assays
1
2020
923
0.030
 Why?
Academic Medical Centers
1
2020
534
0.030
 Why?
Antimicrobial Stewardship
1
2019
128
0.030
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2019
252
0.030
 Why?
Anti-Inflammatory Agents
1
2020
477
0.030
 Why?
Clinical Decision-Making
1
2019
343
0.030
 Why?
Case-Control Studies
1
2024
3601
0.030
 Why?
Neutrophils
1
2022
1142
0.030
 Why?
Acute Disease
1
2019
994
0.030
 Why?
Mice
2
2026
18309
0.030
 Why?
Thoracic Neoplasms
1
2015
39
0.030
 Why?
Abdominal Neoplasms
1
2015
47
0.030
 Why?
Tosyl Compounds
1
2015
16
0.030
 Why?
Antibodies, Neoplasm
1
2015
33
0.030
 Why?
Kidney Function Tests
1
2015
156
0.030
 Why?
Reaction Time
1
2017
439
0.030
 Why?
Craniocerebral Trauma
1
2017
175
0.030
 Why?
Angiogenesis Inhibitors
1
2016
232
0.030
 Why?
Neoplasm Grading
1
2015
304
0.030
 Why?
Organ Size
1
2015
469
0.030
 Why?
Radiotherapy
1
2015
204
0.030
 Why?
Drug Resistance, Neoplasm
1
2020
866
0.030
 Why?
Radiotherapy Planning, Computer-Assisted
1
2015
146
0.030
 Why?
Postoperative Period
1
2015
351
0.030
 Why?
Demography
1
2015
287
0.030
 Why?
Radiotherapy, Intensity-Modulated
1
2015
137
0.030
 Why?
STAT5 Transcription Factor
1
2014
52
0.030
 Why?
Nitriles
1
2015
188
0.030
 Why?
Animals
3
2026
37909
0.030
 Why?
Recurrence
1
2017
1117
0.030
 Why?
Drug Interactions
1
2015
398
0.030
 Why?
Gonadotropin-Releasing Hormone
1
2015
210
0.020
 Why?
Medication Adherence
1
2017
517
0.020
 Why?
ErbB Receptors
1
2015
616
0.020
 Why?
Cell Survival
1
2015
1104
0.020
 Why?
Longitudinal Studies
1
2020
2930
0.020
 Why?
Proportional Hazards Models
1
2015
1286
0.020
 Why?
Neuropsychological Tests
1
2017
1120
0.020
 Why?
Double-Blind Method
1
2016
1999
0.020
 Why?
T-Lymphocytes, Regulatory
1
2014
390
0.020
 Why?
Molecular Targeted Therapy
1
2014
435
0.020
 Why?
Proto-Oncogene Proteins
1
2014
622
0.020
 Why?
Biomarkers
1
2022
4227
0.020
 Why?
Enzyme Inhibitors
1
2014
828
0.020
 Why?
Logistic Models
1
2015
2088
0.020
 Why?
Cell Cycle Proteins
1
2014
628
0.020
 Why?
Reagent Strips
1
2008
8
0.020
 Why?
Primary Health Care
1
2019
1752
0.020
 Why?
Urinalysis
1
2008
80
0.020
 Why?
Diagnostic Tests, Routine
1
2008
109
0.020
 Why?
Albuminuria
1
2008
186
0.020
 Why?
Vision, Monocular
1
2005
4
0.010
 Why?
Psychophysics
1
2005
15
0.010
 Why?
Eye Enucleation
1
2005
15
0.010
 Why?
Vision, Binocular
1
2005
47
0.010
 Why?
Orientation
1
2005
50
0.010
 Why?
Adolescent
2
2020
22136
0.010
 Why?
Pattern Recognition, Visual
1
2005
103
0.010
 Why?
Photic Stimulation
1
2005
261
0.010
 Why?
Sensitivity and Specificity
1
2008
1976
0.010
 Why?
Signal Transduction
1
2014
5193
0.010
 Why?
Pregnancy
1
2008
7129
0.010
 Why?
Child
1
2005
22376
0.000
 Why?
Lam's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (314) concept(s)
_
Co-Authors Expand Description
See all (48) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)